The potential of pregabalin in neurology, psychiatry and addiction: A qualitative overview

Current Pharmaceutical Design

Volumn 19, Issue 35, 2013, Pages 6367-6374

  Martinotti, Giovanni ^a   Lupi, Matteo ^a   Sarchione, Fabiola ^a   Santacroce, Rita ^a   Salone, Anatolia ^a   De Berardis, Domenico ^a,b   Serroni, Nicola ^a   Cavuto, Marilde ^c   Signorelli, Maria ^d   Aguglia, Eugenio ^d   Valchera, Alessandro ^e   Iasevoli, Felice ^f   Di Giannantonio, Massimo ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b G Mazzini Hospital   (Italy)

^c IASM   (Italy)

^d UNIVERSITY OF CATANIA   (Italy)

^e Hermanas Hospitalarias   (Italy)

^f UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Abuse; Alcohol; Anxiety; Benzodiazepines; Epilepsy; Fibromyalgia; Neuropathic pain; Pregabalin

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ALPRAZOLAM; AMITRIPTYLINE; BENZODIAZEPINE DERIVATIVE; CALCITONIN GENE RELATED PEPTIDE; DULOXETINE; GABAPENTIN; GLUTAMIC ACID; LORAZEPAM; NALTREXONE; NORADRENALIN; PLACEBO; PREGABALIN; SUBSTANCE P; TIAPRIDE; VENLAFAXINE; VOLTAGE GATED CALCIUM CHANNEL;

ALCOHOL WITHDRAWAL; ALCOHOLISM; ALLODYNIA; ANALGESIC ACTIVITY; ANXIETY DISORDER; ARTICLE; BENZODIAZEPINE DEPENDENCE; CENTRAL NERVOUS SYSTEM; DIABETIC NEUROPATHY; DRUG DEPENDENCE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG TOLERANCE; EVENING DOSAGE; FIBROMYALGIA; FOCAL EPILEPSY; GENERALIZED ANXIETY DISORDER; HUMAN; INSOMNIA; MULTICENTER STUDY (TOPIC); NEUROPATHIC PAIN; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; PANIC; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; QUALITATIVE RESEARCH; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RESTLESS LEGS SYNDROME; SEIZURE; SOCIAL PHOBIA; SOMNOLENCE; SYSTEMATIC REVIEW; TRANQUILIZING ACTIVITY;

ANALGESICS; ANIMALS; ANTICONVULSANTS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS; CENTRAL NERVOUS SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; GAMMA-AMINOBUTYRIC ACID; HUMANS; PAIN;

EID: 84887956874     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990425     Document Type: Article

References (80)

1. http://commons. wikimedia. org/wiki/File: Pregabalin Structural Formulae. png.
2. Dooley DJ, Donovan CM, Meder WP, Whetzel SZ. Preferential action of gabapentin and pregabalin at P/Q-type voltage-sensitive calcium channels: inhibition of K+-evoked [3H]-norepinephrine release from rat neocortical slices. Synapse 2002; 45: 171-90.
3. Taylor CP. CNS Drug Rev 2004; 10 (2): 159-64.
4. Palma A, Pancheri P. Anticonvulsants in anxiety disorder and the role of pregabalin. Giorn Ital Psicopat 2007; 13: 105-27.
5. Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapenti. Clin Pharmacokinet 2010 Oct; 49(10): 661-9.
6. Herman AI, Waters AJ, McKee SA, Sofuoglu M. Effects of pregabalin on smoking behavior, withdrawal symptoms, and cognitive performance in smokers. Psychopharmacology (Berl) 2012; 220(3): 611-7.
7. Lozsadi D, Hemming K, Marson AG. Pregabalin add-on for drugresistant partial epilepsy. Cochrane Database Syst Rev 2008(1); CD005612.
8. Warner G, Figgitt DP. Pregabalin: as adjunctive treatment of partial seizures. CNS Drugs 2005; 19(3): 265-72; discussion 273-64.
9. Lauria-Horner BA, Pohl RB. Review of pharmacology and clinical experience. Expert Opin. Invest. Drugs 2003; 12: 663-72.
10. Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology 2004; 63: 2104-110.
11. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 2004; 110(3): 628-38.
12. Toelle T, Versavel M, Glessner C, Trostmann U. A Novel Treatment for Diabetic Peripheral Neuropathy: Pregabalin Dose and Pain Relief. Anesthesiology 2004; 101: A967.
13. Achar A, Chakraborty PP, Bisai S, Biswas A, Guharay T. Comparative study of clinical efficacy of amitriptyline and pregabalin in postherpetic neuralgia. Acta Dermatovenerol Croat 2012; 20(2): 89-94.
14. Dworkin RH, Corbin AE, Young JP Jr, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebocontrolled trial. Neurology 2003; 60: 1274-83.
15. Sabatowski R, Galvez R, Cherry DA, et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with postherpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain 2004; 109: 26-35.
16. Di Iorio G, Matarazzo I, Di Tizio L, Martinotti G. Treatment resistant insomnia treated with pregabalin. Eur Rev Med Pharmacol Sci 2012; Art. 1. 2502.
17. Bansal D, Bhansali A, Hota D, Chakrabarti A, Dutta P. Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial. Diabet Med 2009; 26(10): 1019-26.
18. Boyle J, Eriksson ME, Gribble L, et al. Randomized, Placebo-Controlled Comparison of Amitriptyline, Duloxetine, and Pregabalin in Patients With Chronic Diabetic Peripheral Neuropathic Pain: Impact on pain, polysomnographic sleep, daytime functioning, and quality of life. Diabetes Care 2012; 35(12): 2451-8.
19. [No authors listed]. New drugs from old. Drug Ther Bull 2006; 44(10): 73-7.
20. Cardenas DD, Nieshoff EC, Suda K, et al. A randomized trial of pregabalin in patients with neuropathic pain due to spinal cord injury. Neurology 2013; 80(6): 533-9.
21. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995; 38: 19-28.
22. Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005; 52(4): 1264-73.
23. Mease PJ, Russell IJ, Arnold LM, et al. A randomized, doubleblind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 2008; 35: 502-14.
24. Russell IJ, Crofford LJ, Leon T, et al. The effects of pregabalin on sleep disturbance symptoms among individuals with fibromyalgia syndrome. Sleep Med 2009; 10(6): 604-10.
25. Roth T, Lankford DA, Bhadra P, Whalen E, Resnick EM. Effect of pregabalin on sleep in patients with fibromyalgia and sleep maintenance disturbance: a randomized, placebo-controlled, 2-way crossover polysomnography study. Arthritis Care Res (Hoboken) 2012; 64(4): 597-606.
26. Crofford LJ, Mease PJ, Simpson SL, et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): A 6-month, double-blind, placebo-controlled trial with pregabalin. Pain 2008; 136: 419-31.
27. Sander JW, Shorvon SD. Epidemiology of the epilepsies. J Neurol Neurosurg Psychiatry 1996; 61(5): 433-43.
28. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000; 342(5): 314-9.
29. Kälviäinen R, Khyuppenen J, Koskenkorva P, et al. Clinical picture of EPM1-Unverricht-Lundborg disease. Epilepsia 2008; 49: 549-56.
30. Ryvlin P, Perucca E, Rheims S. Pregabalin for the management of partial epilepsy. Neuropsychiatric Disease and Treatment 2008; 4(6): 1211-24.
31. Amir M Arain. Pregabalin in the management of partial epilepsy. Neuropsychiatric Disease and Treatment 2009; 5 407-13.
32. Bazil CW. Epilepsy and sleep disturbance. Epilepsy Behav 2003; 4 Suppl 2: S39-45.
33. De Haas S, Otte A, De Weerd A, Van Erp G, Cohen A, Van Gerven J. Exploratory Polysomnographic Evaluation of Pregabalin on Sleep Disturbance in Patients with Epilepsy. J Clin Sleep Med 2007; 3(5).
34. Romigi A, Izzi F, Marciani MG. et al. Pregabalin as add-on therapy induces REM sleep enhancement in partial epilepsy: a polysomnographic study. Eur J Neurol 2009; 16: 70-5.
35. Palma A, Pancheri P. Anticonvulsants in anxiety disorder and the role of pregabalin. Giorn Ital Psicopat 2007; 13: 105-27.
36. Pande AC, Crockatt JG, Feltner DE, et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry 2003; 160(3): 533-40.
37. Feltner DE, Crockatt JG, Dubovsky SJ, et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 2003; 23: 240-9.
38. Baldwin DS, Ajel K. Role of pregabalin in the treatment of generalized anxiety disorder. Neuropsychiatr Dis Treat 2007; 3: 185-91.
39. Montgomery SA. Pregabalin for the treatment of generalised anxiety disorder. Expert Opin Pharmacother 2006; 7: 2139-54.
40. Pohl RB, Feltner DE, Fieve RR, et al. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebocontrolled comparison of BID versus TID dosing. J Clin Psychopharmacol 2005; 25: 151-8.
41. Pande AC, Feltner DE, Jefferson JW, et al: Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebocontrolled, multicenter study. J Clin Psychopharmacol 2004; 24(2): 141-9.
42. Martinotti G, Di Nicola M, Romanelli R, et al. High and low dosage oxcarbazepine versus naltrexone for the prevention of relapse in alcohol-dependent patients. Hum Psychopharmacol 2007; 22(3): 149-56.
43. Martinotti G, Romanelli R, Di Nicola M, Reina D, Mazza M, Janiri L. Oxcarbazepine at high dosages for the treatment of alcohol dependence. Am J Addict 2007; 16(3): 247-8.
44. Guglielmo R, Martinotti G, Clerici M, Janiri L. Pregabalin for Alcohol Dependence: A Critical Rev Literature 2012 Adv Ther.
45. Koob GF. A role for GABA mechanisms in the motivational effects of alcohol. Biochem Pharmacol 2004; 68: 1515-25.
46. Martinotti G, Di Nicola M, Frustaci A et al. Pregabalin, tiapride and lorazepam in alcohol withdrawal syndrome: a multi-centre, randomized, single-blind comparison trial. Addiction 2010; 105: 288-99.
47. Littleton J. Neurochemical mechanisms underlying alcohol withdrawal. Alcohol Health Res World 1998; 22: 13-24.
48. Martinotti G, Di Nicola M, Tedeschi D, Mazza M, Janiri L, Bria P. Efficacy and safety of pregabalin in alcohol dependence. Adv Ther 2008; 25: 608-18.
49. Martinotti G, Di Nicola M, Tedeschi D, et al. Pregabalin versus naltrexone in alcohol dependence: a randomised, double-blind, comparison trial. J Psychopharmacol 2010; 24: 1367-74.
50. Hall W., Zador D. The alcohol withdrawal syndrome. Lancet 1997; 349: 1897-900.
51. Kosten TR, O'Connor PG. Management of drug and alcohol withdrawal. N Engl J Med 2003; 348: 1786-95.
52. Swift RM. Drug therapy for alcohol dependence. N Engl J Med 1999; 340: 1482-90.
53. Littleton J. Neurochemical mechanisms underlying alcohol withdrawal. Alcohol Health ResWorld 1998; 22: 13-24.
54. Martinotti G, Nicola MD, Reina D, et al. Alcohol protracted withdrawal syndrome: the role of anhedonia. Subst Use Misuse 2008; 43(3-4): 271-84.
55. Fiellin DA, O'Connor PG, Holmboe ES, Horwitz RI. Risk for delirium tremens in patients with alcohol withdrawal syndrome. Subst Abuse 2002; 23: 83-94.
56. Pieninkeroinen IP, Telakivi TM, Hillbom ME. Outcome in subjects with alcohol-provoked seizures. Alcohol Clin Exp Res 1992; 16: 955-9.
57. Lerner WD, Fallon HJ. The alcohol withdrawal syndrome. N Engl J Med 1985; 313: 951-2.
58. Schuckit MA. Alcoholism acute treatment. In: Schuckit MA, editor. Drug and Alcohol Abuse. A Clinical Guide to Diagnosis and Treatment, New York: Plenum Medical Book Co; 1995, p. 97-117.
59. Lejoyeux M, Solomon J, Ades J. Benzodiazepine treatment for alcohol-dependent patients. Alcohol Alcohol 1998; 33: 563-75.
60. O'Connor PG, Schottenfeld RS. Patients with alcohol problems. N Engl J Med 1998; 338: 592-602.
61. Nutt D, Adinoff B, Linnoila M. Benzodiazepines in the treatment of alcoholism. In: Galanter M., editor. Recent Development in Alcoholism. American Society of Addiction Medicine and Research Society on Alcoholism. New York Plenum Press 1989; p: 283-313.
62. Saitz R, Mayo-Smith MF, Roberts MS, Redmond HA, Bernard DR, Calkins DR. Individualized treatment for alcohol withdrawal. A randomized double-blind controlled trial. JAMA 1994; 272: 519-23.
63. Mayo-Smith M. F. Pharmacologicalmanagement of alcohol withdrawal: a meta-analysis and evidence-based practice guideline: American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. JAMA 1997; 278: 144-51.
64. Saitz R. Clinical practice. Unhealthy alcohol use. N Engl J Med 2005; 352: 596-607.
65. Myrick H, Anton R, Voronin K, Wang W, Henderson S. A doubleblind evaluation of gabapentin on alcohol effects and drinking in a clinical laboratory paradigm. Alcohol Clin Exp Res 2007; 31: 221-7.
66. Ait-Daoud N, Malcolm RJ. Jr, Johnson BA. An overview of medications for the treatment of alcohol withdrawal and alcohol dependencewithanemphasisontheuse of older and newer anticonvulsants. Addict Behav 2006; 31: 1628-49.
67. Ross H. E. Benzodiazepine use and anxiolytic abuse and dependence in treated alcoholics. Addiction 1993; 88: 209-18.
68. Di Nicola M, Tedeschi D, Martinotti G, et al. Pregabalin augmentation in treatment-resistant obsessive-compulsive disorder: a 16-week case series. J Clin Psychopharmacol 2011; 31(5): 675.
69. Martinotti G, Carli V, Tedeschi D, et al. Mono-and polysubstance dependent subjects differ on social factors, childhood trauma, personality, suicidal behaviour, and comorbid Axis I diagnoses. Addict Behav 2009; 34(9): 790-3.
70. Oulis P, Konstantakopoulos G. Efficacy and safety of pregabalin in the treatment of alcohol and benzodiazepine dependence. Exp Opin Investig Drugs 2012; (7): 1019-29.
71. Oulis P, Konstantakopoulos G, Kouzoupis AV, et al. Pregabalin in the discontinuation of long-term benzodiazepines' use. Hum Psychopharmacol 2008; 23(4): 337-40.
72. Shneker BF, McAuley JW. Pregabalin: a new neuromodulator with broad therapeutic indications. Ann Pharmacother 2005; 39: 2029-37.
73. Martinotti G. Pregabalin in clinical psychiatry and addiction: pros and cons. Expert Opin Investig Drugs 2012; 21(9): 1243-5.
74. Psychonaut Web Mapping Research Group (2009). Lyrica Report. Institute of Psychiatry, King's College London, London, UK. Available from: www. psychonautproject. eu (accessed on February 5th, 2010).
75. Carrus D, Schifano F. Pregabalin misuse-related issues; intake of large dosages, drug-smoking allegations, and possible association with myositis: two case reports. J Clin Psychopharmacol. 2012; 32(6): 839-40.
76. Schifano F, D'Offizi S, Piccione M, et al. Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data. Psychother Psychosom 2011; 80(2): 118-22.
77. Skopp G, Zimmer G. Pregabalin-a drug with abuse potential? Arch Kriminol 2012; 229(1-2): 44-54. German.
78. Thomson/Micromedex. Drug Information for the Health Care Professional 2007; Volume 1, Greenwood Village, CO p. 2414.
79. McEvoy GK (ed.) American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda MD 2007; p. 2248.
80. Lowther C. Pregabalin (LyricaR): Part II. Pharmacotherapy update. Volume VIII, No. VI November/December 2005.